Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of fosnetupitant vs fosaprepitant for prevention of cisplatin-induced CINV
jRCT2080224542Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosnetupitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall complete response rate. Started Feb 2019; status: completed.
02
Drugs
fosnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080224542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224542.